The OBS Group is one of Pakistan’s leading corporations in the healthcare segment with presence in Pakistan and Sri Lanka. OBS commenced operations in 1963 and became a name associated with quality medicine throughout Pakistan in 2006 after entering into a strategic alliance with Organon (part of Akzo Nobel). Since then, OBS has fostered strategic alliances with many reputable international firms including Organon, Merck & Co Inc, USA, Schering Plough, AstraZeneca, Mylan USA, Vifor Switzerland and Santen Pharma Japan. At present, OBS ranks as the 8th largest pharmaceutical player in Pakistan amongst 704 companies with a group turnover in excess of PKR 9,300 million and profits of over PKR 2,000 mn. We a have a strong presence all over Pakistan with over 300 professionally trained sales representatives covering more than 25,000 healthcare professionals across the country. Our key focus areas include Anti-Infective, Cardiology, CNS, Diabetes & Metabolic Disorders, Gastroenterology, Ophthalmology, Respiratory, Women’s Health (Infertility, HRT & Contraception) and Vaccines. We have 106 pharmaceutical brands and 7 consumer brands in Pakistan and 12 pharmaceutical brands in Sri Lanka along with a strong presence in Afghanistan. The OBS Group is now looking to tap markets in Vietnam and Uzbekistan with various products which are under registration. We continuously invest on upgrading our information systems which enable us to scientifically grow our business and help the management to have effective controls and further improve efficiency of the organization. In addition to the systems we also strongly believe that people are the most important asset for our organization. We believe in equal employment opportunity and harnessing diversity in our group companies. We regularly invest in the training and development of our human resource through both internal and external training and development programs.